- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04232280
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
December 29, 2023 updated by: ModernaTX, Inc.
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
mRNA-1647-P202 is a 2-part study.
Part 1 of the study evaluates the safety and immunogenicity of 3 dose levels of mRNA-1647 vaccine or placebo, administered on a 0, 2, 6-month schedule in healthy CMV-seronegative and CMV-seropositive males and females, 18 to 40 years of age.
A planned interim analysis of safety and immunogenicity through Month 3 (1 month after the second dose) of Part 1 of the study informed the selection of the middle dose level for further development.
Part 2 of the study is designed to further evaluate the safety and immunogenicity of the middle dose level of mRNA-1647 vaccine or placebo on a 0, 2, 6-month schedule in approximately 200 healthy participants 18 to 40 years of age, comprised of CMV-seronegative and CMV-seropositive female population, which includes the target population for the pivotal Phase 3 efficacy trial.
Study Type
Interventional
Enrollment (Actual)
315
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95864
- Benchmark Research
-
-
Illinois
-
Peoria, Illinois, United States, 61614
- Optimal Research
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- Johnson County Clin-Trials
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Alliance for Multispecialty Research
-
-
Ohio
-
Columbus, Ohio, United States, 43213-6523
- Aventiv Research Inc
-
-
Texas
-
Austin, Texas, United States, 78745
- Tekton Research Inc
-
Victoria, Texas, United States, 77901
- Crossroads Clinical Research
-
-
Utah
-
Salt Lake City, Utah, United States, 84109
- Foothill Family Clinic
-
Salt Lake City, Utah, United States, 84121
- Foothill Family Clinic-South Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male or female 18-40 years of age (Part 1); Female 18-40 years of age (Part 2)
- Understands and agrees to comply with the trial procedures and provides written informed consent
- According to the assessment of the Investigator, is in good general health and is capable of complying with trial procedures
- Body mass index (BMI) 18-35 kilograms/meter (kg/m^2)
- Female participants must either be of non-childbearing potential or use acceptable methods of contraception from at least 28 days prior to the first vaccination and through 3 months following last vaccination and is not breastfeeding.
- Male participants must agree to practice adequate contraception from the time of the first vaccination and through 3 months after the last vaccination.
Exclusion Criteria:
- Acutely ill or febrile on the day of the first vaccination
- Prior receipt of any CMV vaccine
- Abnormal screening safety laboratory test results
- Diagnosis or condition that, in the judgment of Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to trial procedures
- Has received or plans to receive a vaccine ≤28 days prior to the first vaccination or plans to receive a non-study vaccine within 28 days prior to or after any study vaccination, except for any licensed influenza vaccine which can be administered >14 days before or after any study vaccination. COVID-19 vaccines (regardless of manufacturer) may be administered >7 days but preferably >14 days before or after any study vaccination, with the intention of prioritizing COVID-19 vaccination over all other considerations.
- Prior receipt of chronic systemic immunosuppressants or immune-modifying drugs
- Receipt of intravenous immunoglobulins or plasma products within 3 months prior to the day of the first study vaccination
- Previous receipt of medications in lipid nanoparticle (LNP) formulation (Part 1 participants only)
- Has donated ≥450 milliliters (mL) of blood products within 28 days of the Screening visit
- Participated in an interventional clinical trial within 28 days prior to the day of enrollment
- Is an immediate family member or household member of trial personnel
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants will receive placebo matching to the mRNA-1647 vaccine dose by IM injection on Day 1, Day 56, and Day 168.
|
0.9% sodium chloride (normal saline) injection
|
Experimental: mRNA-1647 Dose Level A
Participants will receive mRNA-1647 vaccine at Dose Level A by intramuscular (IM) injection on Day 1, Day 56, and Day 168.
|
Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
|
Experimental: mRNA-1647 Dose Level B
Participants will receive mRNA-1647 vaccine at Dose Level B by IM injection on Day 1, Day 56, and Day 168.
|
Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
|
Experimental: mRNA-1647 Dose Level C
Participants will receive mRNA-1647 vaccine at Dose Level C by IM injection on Day 1, Day 56, and Day 168.
|
Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of Solicited Local and Systemic Adverse Reactions (ARs)
Time Frame: Up to Day 175 (7 days following last dose administration)
|
Up to Day 175 (7 days following last dose administration)
|
Frequency of Unsolicited Adverse Events (AEs)
Time Frame: Up to Day 196 (28 days following last dose administration)
|
Up to Day 196 (28 days following last dose administration)
|
Frequency of Medically-Attended Adverse Events (MAAEs)
Time Frame: Up to Day 336 (6 months following last dose administration)
|
Up to Day 336 (6 months following last dose administration)
|
Frequency of Serious Adverse Events (SAEs)
Time Frame: Up to Day 504 (1 year following last dose administration)
|
Up to Day 504 (1 year following last dose administration)
|
Change from Baseline in Geometric Mean Titer (GMT) of Serum Neutralizing Anti-CMV Antibodies Against Epithelial Cell Infection and Against Fibroblast Infection
Time Frame: Baseline, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Baseline, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Proportion of Participants with ≥2-Fold, 3-Fold, and 4-Fold Increases in Neutralizing Antibodies (nAb) over Baseline Against Epithelial Cell Infection and Against Fibroblast Infection
Time Frame: Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, and Day 504
|
Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, and Day 504
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in GMT of Anti-Glycoprotein B (gB) Specific Immunoglobulin G (IgG) and Anti-Pentamer Specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) of Post-Baseline/Baseline Titers
Time Frame: Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Change from Baseline in Associated GMR of Anti-gB Specific IgG and Anti-Pentamer Specific IgG as Measured by ELISA of Post-Baseline/Baseline Titers
Time Frame: Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Change from Baseline in GMT of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group
Time Frame: Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Change from Baseline in GMR of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group
Time Frame: Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Proportion of Participants with ≥2-Fold, 3-Fold, and 4-Fold Increases over Baseline of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection
Time Frame: Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, and Day 504
|
Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, and Day 504
|
Change from Baseline in GMT of Antigen-Specific IgG (ELISA) at each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups
Time Frame: Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Change from Baseline in GMR of Antigen-Specific IgG (ELISA) at each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups
Time Frame: Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 9, 2020
Primary Completion (Actual)
January 4, 2023
Study Completion (Actual)
January 4, 2023
Study Registration Dates
First Submitted
January 9, 2020
First Submitted That Met QC Criteria
January 14, 2020
First Posted (Actual)
January 18, 2020
Study Record Updates
Last Update Posted (Actual)
January 3, 2024
Last Update Submitted That Met QC Criteria
December 29, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- mRNA-1647-P202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus Infection
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
Jun ZhangNational Natural Science Foundation of China; Merck Sharp & Dohme LLCCompletedCongenital Cytomegalovirus Infection | Cytomegalovirus Infection ReactivationChina
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus InfectionUnited States, France, Germany, Italy, Japan, United Kingdom
-
Foundation IRCCS San Matteo HospitalFondazione Regionale per la Ricerca Biomedica (FRRB) - Regione LombardiaUnknownCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionItaly
-
Assistance Publique - Hôpitaux de ParisCompletedFoetuses Infection | Cytomegalovirus (CMV)InfectionFrance
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Institut PasteurCompletedCongenital Cytomegalovirus InfectionFrance
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
Assistance Publique - Hôpitaux de ParisTerminatedCytomegalovirus Infection | Viral DiseaseFrance
Clinical Trials on mRNA-1647
-
ModernaTX, Inc.CompletedCytomegalovirus InfectionUnited States
-
ModernaTX, Inc.Active, not recruitingCytomegalovirus | SARS-CoV-2 | Seasonal Influenza | Respiratory Syncytial VirusUnited States
-
ModernaTX, Inc.Enrolling by invitationCytomegalovirus InfectionUnited States
-
ModernaTX, Inc.CompletedCytomegalovirus InfectionUnited States
-
ModernaTX, Inc.Active, not recruitingCytomegalovirusUnited Kingdom, United States, Canada
-
ModernaTX, Inc.Recruiting
-
ModernaTX, Inc.Active, not recruitingCytomegalovirus InfectionUnited States, Australia, Canada, France, Belgium, Germany, Israel, Italy, United Kingdom, Spain, Estonia, Finland, Japan
-
ModernaTX, Inc.WithdrawnCytomegalovirus InfectionUnited States
-
ModernaTX, Inc.Completed
-
ModernaTX, Inc.Active, not recruitingA Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsInfluenza | SARS-CoV-2United States